Literature DB >> 4380880

Treatment of narcolepsy with imipramine (tofranil) and desmethylimipramine (pertofran).

Y Hishikawa, H Ida, K Nakai, Z Kaneko.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1966        PMID: 4380880     DOI: 10.1016/0022-510x(66)90001-3

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


× No keyword cloud information.
  15 in total

1.  Editorial: Narcolepsy.

Authors: 
Journal:  Br Med J       Date:  1975-03-01

Review 2.  Cataplexy associated with narcolepsy: epidemiology, pathophysiology and management.

Authors:  Michael J Thorpy
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

3.  Symptomatic cataplexy.

Authors:  M Anderson; M V Salmon
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-02       Impact factor: 10.154

4.  Narcolepsy.

Authors:  T J Murray; A Foley
Journal:  Can Med Assoc J       Date:  1974-01-05       Impact factor: 8.262

Review 5.  Challenges in the development of therapeutics for narcolepsy.

Authors:  Sarah Wurts Black; Akihiro Yamanaka; Thomas S Kilduff
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

Review 6.  Clinical and neurobiological aspects of narcolepsy.

Authors:  Seiji Nishino
Journal:  Sleep Med       Date:  2007-04-30       Impact factor: 3.492

Review 7.  Benefits and risks of pharmacotherapy for narcolepsy.

Authors:  Merrill M Mitler; Roza Hayduk
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

8.  Fluvoxamine and clomipramine in the treatment of cataplexy.

Authors:  M Schachter; J D Parkes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-02       Impact factor: 10.154

Review 9.  Therapeutic Symptomatic Strategies in the Parasomnias.

Authors:  Raffaele Manni; Gianpaolo Toscano; Michele Terzaghi
Journal:  Curr Treat Options Neurol       Date:  2018-06-05       Impact factor: 3.598

10.  Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers.

Authors:  E Mignot; A Renaud; S Nishino; J Arrigoni; C Guilleminault; W C Dement
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.